Anti-inflammatory therapy in Alzheimer's disease: is hope still alive? - PubMed (original) (raw)

Review

Anti-inflammatory therapy in Alzheimer's disease: is hope still alive?

W A van Gool et al. J Neurol. 2003 Jul.

Abstract

Based on observations from neuropathology, epidemiology, and in vitro and animal experiments, the inflammatory component of Alzheimer's disease (AD) has been considered a compelling target for therapeutic intervention. However, a summary of all published trial reports to date suggests that AD patients do not benefit from treatment with anti-inflammatory drugs. In this brief review, we try to reconcile these sobering trial results with recent observations from basic research and epidemiology that continue to strengthen the idea that inflammatory mechanisms play an important role in the pathogenesis of AD. We review the possibilities that (1) not all components of the inflammatory response in AD are detrimental, (2) beneficial effects of anti-inflammatory drugs may not be mediated by inflammatory pathways, and (3) the timing of the intervention should be in the earliest stages of the pathogenesis of AD, perhaps even before the first symptoms emerge. We conclude that studies on primary prevention of AD are the logical next step in testing the inflammatory hypothesis of AD.

PubMed Disclaimer

Similar articles

• Inflammatory processes and Alzheimer's disease.
  Walsh S, Aisen PS. Walsh S, et al. Expert Rev Neurother. 2004 Sep;4(5):793-8. doi: 10.1586/14737175.4.5.793. Expert Rev Neurother. 2004. PMID: 15853506 Review.
• Inflammation and Alzheimer's disease.
  Gupta A, Pansari K. Gupta A, et al. Int J Clin Pract. 2003 Jan-Feb;57(1):36-9. Int J Clin Pract. 2003. PMID: 12587940 Review.
• [Inflammation and Alzheimer's disease].
  de Toledo M. de Toledo M. Rev Neurol. 2006 Apr 1-15;42(7):433-8. Rev Neurol. 2006. PMID: 16602061 Review. Spanish.
• Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).
  Meinert CL, Breitner JC. Meinert CL, et al. Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S7-S14. doi: 10.1016/j.jalz.2007.10.007. Epub 2007 Dec 21. Alzheimers Dement. 2008. PMID: 18632005
• Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease.
  Maczurek A, Hager K, Kenklies M, Sharman M, Martins R, Engel J, Carlson DA, Münch G. Maczurek A, et al. Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1463-70. doi: 10.1016/j.addr.2008.04.015. Epub 2008 Jul 4. Adv Drug Deliv Rev. 2008. PMID: 18655815 Review.

Cited by

• Design, Synthesis and Biological Evaluation of New Imidazo[2,1-b]Thiazole Derivatives as Selective COX-2 Inhibitors.
  Shahrasbi M, Azami Movahed M, Ghorban Dadras O, Daraei B, Zarghi A. Shahrasbi M, et al. Iran J Pharm Res. 2018 Fall;17(4):1288-1296. Iran J Pharm Res. 2018. PMID: 30568687 Free PMC article.
• Design, synthesis and biological evaluation of new 5,5-diarylhydantoin derivatives as selective cyclooxygenase-2 inhibitors.
  Zarghi A, Javid FS, Ghodsi R, Dadrass OG, Daraei B, Hedayati M. Zarghi A, et al. Sci Pharm. 2011 Jul-Sep;79(3):449-60. doi: 10.3797/scipharm.1104-20. Epub 2011 Jul 25. Sci Pharm. 2011. PMID: 21886896 Free PMC article.
• COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.
  Riedel M, Strassnig M, Schwarz MJ, Müller N. Riedel M, et al. CNS Drugs. 2005;19(10):805-19. doi: 10.2165/00023210-200519100-00001. CNS Drugs. 2005. PMID: 16185091 Review.
• Function and comorbidities of apolipoprotein e in Alzheimer's disease.
  Leduc V, Domenger D, De Beaumont L, Lalonde D, Bélanger-Jasmin S, Poirier J. Leduc V, et al. Int J Alzheimers Dis. 2011 Apr 5;2011:974361. doi: 10.4061/2011/974361. Int J Alzheimers Dis. 2011. PMID: 21559182 Free PMC article.
• The significance of neuroinflammation in understanding Alzheimer's disease.
  Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, van Gool WA, Hoozemans JJ. Eikelenboom P, et al. J Neural Transm (Vienna). 2006 Nov;113(11):1685-95. doi: 10.1007/s00702-006-0575-6. Epub 2006 Oct 13. J Neural Transm (Vienna). 2006. PMID: 17036175 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information